Imagion Biosystems announces on ASX that it has received a total of $3500 for the exercise of 70,000 Listed Options exercisable at 5 cents, expiring on 26 November 2021.
Please click to review the full announcement at ASX.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
July 15, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging